HARP
$15.33
Harpoon Therapeutics
$.08
.52%
HARP
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.45)
Revenue:  $7.02 Mil
Thursday
Aug 5
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when HARP reports earnings?
Beat
Meet
Miss

Where is HARP's stock price going from here?
Up
Flat
Down
Stock chart of HARP
Analysts
Summary of analysts' recommendations for HARP
Score
Grade
Pivots
Resistance
$16.17
$15.98
$15.65

$15.46

Support
$15.13
$14.94
$14.61
Tweet
Growth
Description
Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of the body's immune system to treat patients suffering from cancer and other diseases. Using its proprietary Tri-specific T cell Activating Construct(TM) platform, they are developing a pipeline of novel T cell engagers, focused on the treatment of solid tumors and hematologic malignancies. Harpoon Therapeutics Inc. is based in San Francisco, United States.